



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	09/932677-Conf. #5945	
			Filing Date	August 16, 2001	
			First Named Inventor	Donald F. WEAVER	
			Art Unit	1624	
Examiner Name	D. R. Rao				
Sheet	1	of	2	Attorney Docket Number	NCI-006DV1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
DR	A1*	US-5,252,576	10-12-1993	Sakata et al.	
DR	A2*	US-6,306,909	10-23-2001	Weaver et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
DR	B1	JP-61236724	10-22-1986	Kyowa Hakko Kogyo Co. Ltd.		Abstr.
DR	B2	EP-0343050-B1	12-02-1992	Synthelabo		Abstr.
DR	B3	DE-4300912-A1	07-21-1994	Merck Patent GmbH		Abstr.
DR	B4	WO-95/19346-A1	07-20-1995	Sandoz Ltd.		
DR	B5	EP-0718280-A2	06-26-1996	Isagro Ricerca		
DR	B6	WO-98/27972-A2	07-02-1998	Texas A&M University		
DR	B7	GB-2327672	02-03-1999	Merck & Co. Inc.		
DR	B8	WO-9951572-A1	10-14-1999	Sankyo Company Limited		Abstr.
DR	B9	WO-99/52493-A3	10-21-1999	Texas Biotechnology Corporation		
DR	B10	WO-00/06570-A1	02-10-2000	Ortho-McNeil Pharmaceutical, Inc.		
DR	B11	WO-00/11952-A1	03-09-2000	Pro-Neuron, Inc.		
DR	B12	WO-00/50043-A1	08-31-2000	The Regents of the University of California		
DR	B13	WO-00/56715-A1	09-28-2000	Ortho-McNeil Pharmaceutical, Inc.		
DR	B14	WO-01/51490-A1	07-19-2001	The Government of the United States of America		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DR	C1	Baker, B.R., et al., "Irreversible Enzyme Inhibitors. LXXX.1.2 Inhibitors of Thymidine Phosphorylase. VI.2 Hydrophobic Bonding with 6 Substituents on the Acidic 5-Nitro- and 5-Bromouracils," <i>J. Med. Chem.</i> , Vol. 10(3):316-320 (1967)	
DR	C2	Huxtable, R., et al., "The prolonged anticonvulsant action of taurine on genetically determined seizure-susceptibility," <i>CAPLUS</i> , Accession No. 1978:470974, 1 page (1978)	
DR	C3	Connolly, Gerald P., et al., "Uridine and its nucleotides: biological actions, therapeutic potentials," <i>TIPS</i> , Vol. 20:218-225 (1999)	

Examiner Signature	<i>Deepak Ray</i>	Date Considered	4/17/06.
-----------------------	-------------------	--------------------	----------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/932677-Conf. #5945	
			Filing Date	August 16, 2001	
			First Named Inventor	Donald F. WEAVER	
			Art Unit	1624	
			Examiner Name	D. R. Rao	
Sheet	2	of	2	Attorney Docket Number	NCI-006DV1

WOR	C4	Matsui, Masaki, et al., "Ozonolysis of Substituted Uracils," <i>J. Org. Chem.</i> , Vol. 55:1396-1399 (1990)	
WOR	C5	Skulnick, Harvey I., et al., "Pyrimidinones. 3. N-Substituted 6-Phenylpyrimidinones and Pyrimidinediones with Diuretic/Hypotensive and Antiinflammatory Activity," <i>J. Med. Chem.</i> , Vol. 29:1499-1504 (1986)	
WOR	C6	Tateoka, Yuji, et al., "Potentiating Effects of N1, N3-Diallyluracil, N1, N3-Diallylthymine and N1, N3-Diallyl-6-methyluracil on Pentobarbital-Induced Sleep and Diazepam-Induced Motor Incoordination," <i>Chem. Pharm. Bull.</i> , Vol. 35(12):4928-4934 (1987)	
WOR	C7	Temkin, Nancy R., et al., "Antiepileptogenic Agents, How Close Are We?" <i>Drugs</i> , Vol. 61(8):1045-1055 (2001)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Deepak Ray B	Date Considered	4/17/06
-----------------------	--------------	--------------------	---------



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/932677-Conf. #5945	
			Filing Date	August 16, 2001	
			First Named Inventor	Donald F. WEAVER	
			Art Unit	1624	
			Examiner Name	D. R. Rao	
Sheet	1	of	1	Attorney Docket Number	NCI-006DV1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
NR	A1*	US-4,906,779	03-06-1990	Weber et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
NR	B1	GB-953997	04-02-1964	A.E.C. Societe De Chimie Organique et Biologique		
NR	B2	WO-95/12400-A1	05-11-1995	The UAB Research Foundation		
NR	B3	WO-96/17832-A1	06-13-1996	Wamer-Lambert Company		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
NR	C1	European Search Report Application No. 98910555.6, dated November 16, 2005	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Drupak Ray</i>	Date Considered	4/17/06
-----------------------	-------------------	--------------------	---------